Imidazoline receptors. Historic review and current status of knowledge.
DOI:
https://doi.org/10.20344/amp.3166Abstract
After the initial demonstration, by Ruffolo in 1977, that imidazolines and phenethylamines do not interact in the same manner with adrenoceptors, a different class of receptors (imidazoline-preferring receptors) was identified. They are present in the brain stem and in several tissues at the periphery. This imidazoline-preferring receptor is believed to be the target of the anti-hypertensive effect of clonidine and the newly developed clonidine-related substances, rilmenidine and moxonidine. This review summarises the current knowledge and latest developments in this field, including the consensus on the nomenclature proposed by Ernsberger to classify the imidazoline receptors in I1 (clonidine and idazoxan sensitive) and I2 (idazoxan sensitive but clonidine insensitive) types.Downloads
Downloads
How to Cite
Issue
Section
License
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.